Orexin receptor antagonists for major depressive disorder: perspectives from a systematic review and meta-analysis

Molecular Psychiatry 2026 Open access

Read full text
Authors: Taro Kishi, Kenji Sakuma, Masakazu Hatano, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
DOI: 10.1038/s41380-026-03599-z
Cited by: 1
References: 13

Abstract

A recent report by Dr. Hashimoto in Molecular Psychiatry highlighted that, because the orexin system in mesolimbic pathways modulates reward and motivation, it is important to monitor mood changes in individuals with insomnia treated with orexin receptor antagonists (QXR-ANTs) [ 1 ]. Orexin receptors comprise two subtypes: OX1R and OX2R.

Fields of Study & Subjects

Sleep and Wakefulness Research Sleep and related disorders Sleep and Work-Related Fatigue

Publication details

Journal / source
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Volume
31
Issue
8
Pages
4774–4776
Publication date
6 April 2026
Language
EN